bioMérieux: Diagnostics and the Razor-Blade Model

bioMérieux does not cure disease — it identifies it, and it has built a highly profitable, remarkably stable business out of that single mission. By placing its testing machines everywhere and selling the consumables they need forever after, it turned diagnostics into a stream of recurring revenue. This article explains the razor-and-blade model, why diagnostics is such a good business, and how family ownership shaped a 60-year champion.

bioMérieux is also a reminder that not every great health company makes drugs. Diagnostics — knowing precisely what is wrong — is the essential first step of medicine, and the companies that dominate it can be every bit as durable and profitable as the drugmakers whose treatments depend on an accurate diagnosis in the first place.

What is bioMérieux and what does it do?

bioMérieux is a French multinational and a world leader in in-vitro diagnostics (IVD) — the medical tests performed on samples like blood, tissue or swabs, outside the body, to detect and identify disease. Its main focus is infectious diseases: identifying the bacteria, viruses or fungi causing an infection, and determining which antibiotics will work against them.

Based near Lyon and generating around €4 billion in 2024 revenue, with over 90% of sales outside France, bioMérieux sells diagnostic systems — instruments, reagents, software and services — to hospitals, clinical laboratories and industry. Its flagship products include the BIOFIRE panels, which rapidly test a single sample for many possible pathogens at once, and SPOTFIRE, a newer point-of-care version.

Beyond healthcare, bioMérieux also serves industrial customers — testing food, pharmaceuticals and cosmetics for microbial contamination to ensure safety. But its heart is medical diagnostics, and specifically the fight against infection and antimicrobial resistance, a mission it has pursued for 60 years.

How does the razor-and-blade model work?

bioMérieux’s business rests on the ‘razor-and-blade’ model: it sells or places diagnostic instruments (the ‘razors’) in labs and hospitals, often at low margin, then earns the real, recurring profit from the reagents and test kits (the ‘blades’) that those machines must use for every test they run.

This model is powerful because it converts a one-off equipment sale into a long-term stream of consumable revenue. Once a hospital installs a BIOFIRE system and trains its staff on it, that machine keeps consuming bioMérieux’s proprietary test kits for years, generating steady, predictable, high-margin sales. The installed base of instruments becomes an annuity of reagent demand.

The more instruments bioMérieux places, the larger and more valuable this annuity grows, which is why the company works hard to expand its installed base even when the machines themselves earn little. Each new instrument is effectively a subscription sold in advance — a commitment by that lab to keep buying bioMérieux consumables for as long as the machine runs. Over thousands of hospitals and laboratories worldwide, these commitments compound into a large, dependable and highly visible revenue stream that smooths out the company’s earnings and funds its research.

It also creates strong customer lock-in. The instruments are designed to use bioMérieux’s own consumables, so once a lab adopts the platform, switching to a competitor means replacing equipment and retraining staff — costly and disruptive. This razor-and-blade dynamic, familiar from Safran‘s jet engines and printer cartridges alike, gives bioMérieux durable, recurring revenue and a defensible position, and is the key to why diagnostics is such an attractive business.

Why is diagnostics such a good business?

Diagnostics is an attractive business because it combines recurring revenue, high barriers to entry, and essential, growing demand. The razor-and-blade model provides steady consumable sales; the science and regulation involved make it hard for new competitors to enter; and the need for accurate, rapid testing only grows as medicine advances and threats like antimicrobial resistance mount.

Diagnostics also punches above its weight in importance: tests guide a large share of medical decisions while costing a small fraction of total healthcare spending, making them highly valued by health systems seeking to treat patients correctly and cheaply. Rapid, accurate identification of an infection — and of which drug will beat it — saves lives, curbs unnecessary antibiotic use, and reduces costly complications.

bioMérieux’s focus on infectious-disease diagnostics places it at the centre of major global health priorities: pandemic preparedness, hospital-infection control, and the fight against antibiotic resistance. This gives its business both commercial durability and genuine public-health significance — a combination that has made it a resilient grower through economic cycles and health crises alike, delivering double-digit sales growth in 2024.

How does the Mérieux family shape the company?

bioMérieux is publicly listed but firmly controlled by the Mérieux family, through their holding company Institut Mérieux, with Alexandre Mérieux serving as chairman. The family’s involvement in microbiology stretches back over a century, and bioMérieux was founded in 1963 by Alain Mérieux, giving the company a rare depth of dynastic expertise in its field.

This family control gives bioMérieux a long-term, mission-driven character. Rather than chasing short-term profits or diversifying widely, it has stayed focused on diagnostics for decades, investing patiently in research and building its installed base — a consistency that suits a business where trust, regulatory approval and scientific reputation are built slowly. The family’s scientific heritage and long horizon echo the family-stewardship model seen across the France Company Stories hub, applied here to the specialised world of medical diagnostics.

The broader Mérieux ecosystem — spanning vaccines, diagnostics and public-health philanthropy through Institut Mérieux — reflects a family mission around fighting infectious disease that goes beyond pure commerce. That sense of purpose, combined with the discipline of a listed company, has helped bioMérieux remain a focused, respected leader rather than drifting into unrelated ventures.

Why does antimicrobial resistance matter to bioMérieux?

Antimicrobial resistance (AMR) — the growing tendency of bacteria to survive the antibiotics meant to kill them — is one of the great health threats of the century, and it sits at the heart of bioMérieux’s mission and opportunity. As resistance spreads, rapidly identifying exactly which pathogen is infecting a patient, and which drugs will still work, becomes ever more critical.

bioMérieux’s diagnostics directly address this: by quickly pinpointing the cause of an infection and testing its susceptibility to antibiotics, its systems help doctors prescribe the right drug rather than resorting to broad-spectrum antibiotics that fuel further resistance. This makes the company not just a commercial supplier but a key tool in a global public-health battle, aligning its growth with one of medicine’s most urgent needs and underpinning long-term demand for its tests.

How is bioMérieux innovating in rapid testing?

bioMérieux’s technological edge increasingly lies in speed and simplicity — moving diagnostics from slow, specialised central laboratories toward rapid tests that deliver answers in around an hour, closer to the patient. Its BIOFIRE technology can screen a single sample for dozens of possible pathogens simultaneously, and its newer SPOTFIRE system brings that power to smaller settings like emergency rooms and clinics.

This shift matters because speed saves lives and money in infectious disease: the sooner doctors know exactly what is infecting a patient, the sooner they can give the right treatment and stop guessing. Faster, easier-to-use tests also expand the market, letting more settings adopt molecular diagnostics that once required a full laboratory. By leading this move toward rapid, syndromic and point-of-care testing, bioMérieux both strengthens its competitive position and enlarges its installed base — planting more ‘razors’ whose ‘blades’ it will sell for years. It is a strategy of deepening its moat by making its core science ever faster and more accessible.

What are the risks facing bioMérieux?

bioMérieux faces intense competition from larger diagnostics and life-sciences companies, some with far greater resources, and the constant need to innovate as testing technology evolves rapidly. Its results can be affected by the ebb and flow of infectious-disease activity — demand surges during outbreaks and can soften afterwards, as seen with the rise and fall of pandemic-era testing.

It is also exposed to healthcare budget pressures, as hospitals and labs seek to control costs, and to the regulatory demands and reimbursement decisions that govern which tests get adopted and paid for. Currency swings affect its heavily international revenue, and sustaining its technological edge — keeping its instruments and reagents ahead of rivals — requires continuous, heavy R&D investment. Concentration in infectious-disease diagnostics, while a strength, also ties its fortunes to that field.

What can founders learn from bioMérieux?

bioMérieux is a masterclass in the razor-and-blade model and the power of recurring revenue. By placing instruments and then selling the consumables they endlessly require, it turned diagnostics into a stream of predictable, high-margin, defensible income — a model any founder can learn from when designing a business around repeat purchases rather than one-off sales.

It also demonstrates the strength of focus and patient family ownership: by staying dedicated to diagnostics for 60 years, under a family with deep scientific roots, bioMérieux built genuine world leadership in its niche rather than spreading itself thin. For anyone studying the France Company Stories hub, it is the case study in specialised, recurring-revenue businesses and long-term stewardship — proof that a quiet, focused champion can be as durable and valuable as any household name. Explore the pharma, eyewear and cosmetics champions around it across the Pharma, Health & Cosmetics pillar.

Frequently Asked Questions